Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
10 2020
Historique:
received: 26 08 2019
accepted: 20 12 2019
pubmed: 22 1 2020
medline: 4 5 2021
entrez: 22 1 2020
Statut: ppublish

Résumé

Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeO HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO These data indicate that CeO

Sections du résumé

BACKGROUND AND AIMS
Despite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeO
APPROACH AND RESULTS
HCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO
CONCLUSIONS
These data indicate that CeO

Identifiants

pubmed: 31961955
doi: 10.1002/hep.31139
pmc: PMC7702051
doi:

Substances chimiques

alpha-Fetoproteins 0
Cerium 30K4522N6T
ceric oxide 619G5K328Y

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1267-1282

Informations de copyright

© 2020 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases.

Références

Int J Nanomedicine. 2018 Mar 15;13(T-NANO 2014 Abstracts):39-41
pubmed: 29593393
Nanomedicine. 2010 Oct;6(5):698-705
pubmed: 20172051
Chem Commun (Camb). 2010 Apr 28;46(16):2736-8
pubmed: 20369166
Cell Death Dis. 2018 May 23;9(6):620
pubmed: 29795111
Biol Trace Elem Res. 2020 Jan;193(1):214-225
pubmed: 30993490
J Hepatol. 2005 Jun;42(6):842-9
pubmed: 15885355
Am J Pathol. 2003 Oct;163(4):1301-11
pubmed: 14507639
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925
Cell Death Dis. 2013 Aug 29;4:e783
pubmed: 23990023
J Carcinog. 2006 May 11;5:14
pubmed: 16689993
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Hepatol. 2012 Apr;56(4):952-64
pubmed: 22173168
Mol Cancer Ther. 2008 Oct;7(10):3129-40
pubmed: 18852116
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancer Lett. 2013 Feb 1;329(1):74-83
pubmed: 23111106
Biomaterials. 2008 Jun;29(18):2705-9
pubmed: 18395249
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
Cardiovasc Res. 2007 Feb 1;73(3):549-59
pubmed: 17207782
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Gut. 2009 Jan;58(1):118-25
pubmed: 18829979
Biochem Biophys Res Commun. 2006 Mar 31;342(1):86-91
pubmed: 16480682
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
Hepatology. 2012 Aug;56(2):769-75
pubmed: 22378017
J Nanobiotechnology. 2019 Oct 31;17(1):112
pubmed: 31672158
ACS Nano. 2013 Dec 23;7(12):10726-32
pubmed: 24215500
Lipids Health Dis. 2017 Apr 11;16(1):64
pubmed: 28395666
Elife. 2019 Mar 29;8:
pubmed: 30924770
J Adv Res. 2018 Mar 13;11:23-32
pubmed: 30034873
J Hepatol. 2016 Mar;64(3):691-8
pubmed: 26519601
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Angew Chem Int Ed Engl. 2012 Oct 29;51(44):11039-43
pubmed: 22968916
Eur J Med Chem. 2016 Feb 15;109:314-41
pubmed: 26807863
Nano Lett. 2005 Dec;5(12):2573-7
pubmed: 16351218
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
World J Diabetes. 2011 Nov 15;2(11):204-10
pubmed: 22087357
Environ Sci Technol. 2008 Jul 1;42(13):5014-9
pubmed: 18678042
Nat Nanotechnol. 2006 Nov;1(2):142-50
pubmed: 18654167
J Cell Physiol. 2019 Apr;234(4):4987-4996
pubmed: 30187476
ACS Appl Mater Interfaces. 2016 Nov 23;8(46):31510-31523
pubmed: 27933980
Front Immunol. 2017 Aug 14;8:970
pubmed: 28855907
Sci Rep. 2019 Sep 6;9(1):12848
pubmed: 31492960
Carcinogenesis. 2001 May;22(5):795-804
pubmed: 11323400
Int J Biochem Cell Biol. 2017 Oct;91(Pt B):102-115
pubmed: 28552434
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Guillermo Fernández-Varo (G)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Departament of Biomedicine, University of Barcelona, Barcelona, Spain.

Meritxell Perramón (M)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Silvia Carvajal (S)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Denise Oró (D)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Eudald Casals (E)

School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China.

Loreto Boix (L)

Barcelona-Clinic Liver Cancer Group, Liver Unit, Hospital Clinic de Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Laura Oller (L)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Laura Macías-Muñoz (L)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Santi Marfà (S)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Gregori Casals (G)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Working Group for the Biochemical Assessment of Hepatic Disease-SEQCML, Barcelona, Spain.

Manuel Morales-Ruiz (M)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Departament of Biomedicine, University of Barcelona, Barcelona, Spain.
Working Group for the Biochemical Assessment of Hepatic Disease-SEQCML, Barcelona, Spain.

Pedro Casado (P)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Pedro R Cutillas (PR)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Jordi Bruix (J)

Barcelona-Clinic Liver Cancer Group, Liver Unit, Hospital Clinic de Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Miquel Navasa (M)

Liver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Josep Fuster (J)

Liver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Juan Carlos Garcia-Valdecasas (JC)

Liver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Mihai C Pavel (MC)

Liver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.

Víctor Puntes (V)

Institut Català de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Institut Català de Nanociència i Nanotecnologia (ICN2), Bellaterra, Spain.
Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.

Wladimiro Jiménez (W)

Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Departament of Biomedicine, University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH